MedTrace Logo

DV2-HBV-27: Observational Pregnancy Registry

NCT03664648 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2023-09-18

No results posted yet for this study

Summary

Purpose of the study is to evaluate pregnancy outcomes among women who received a dose of HEPLISAV-B within 28 days prior to conception or at any time during pregnancy

Conditions

  • Pregnant

Interventions

BIOLOGICAL

HEPLISAV-B

This study is strictly observational. Administration of HEPLISAV-B, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.

Sponsors & Collaborators

  • PPD, Part of Thermo Fisher Scientific

    collaborator INDUSTRY

  • Dynavax Technologies Corporation

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-21
Primary Completion
2024-09-30
Completion
2024-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03664648 on ClinicalTrials.gov